Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Bayer to Replace CEO Werner Baumann With Former Roche Executive
01:41pm, Wednesday, 08'th Feb 2023
New Chief Executive Bill Anderson will confront the company's legal troubles and its $43 billion in debt.
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
06:04pm, Thursday, 02'nd Feb 2023
Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.
Roche Holding AG (RHHBY) Q4 2022 Earnings Call Transcript
04:02pm, Thursday, 02'nd Feb 2023
Roche Holding AG (OTCQX:RHHBY) Q4 2022 Earnings Conference Call February 2, 2023 8:00 AM ET Company Participants Severin Schwan - CEO & Executive Director Thomas Schinecker - CEO, Roche Diagnostics Ma
Overall we achieved good results, delivered on our numbers and targets: Roche CEO
04:58am, Thursday, 02'nd Feb 2023
Severin Schwan discusses the company's full-year earnings and outlook for the business in the year ahead.
Roche profit misses forecasts, sees COVID-19 related sales decline ahead
01:47am, Thursday, 02'nd Feb 2023
Roche Holding AG reported sales growth in 2022, but said it expects a decrease in sales for 2023 due to a drop in the sale of Covid-19 products.
Barron's And Bloomberg 2023 Ideal Dividend Stocks Of The Year
05:13pm, Tuesday, 31'st Jan 2023
Two Barron's Annual Roundtable, plus one Bloomberg Intelligence articles published late-January listed 99 intriguing stocks for 2023; 77 were unduplicated US publicly-listed companies, of which, 56 pa
Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal
12:02pm, Thursday, 19'th Jan 2023
Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.
Roche (RHHBY) Gets EU Approval for Xofluza in New Patient Base
02:18pm, Thursday, 12'th Jan 2023
The European Commission approves Roche's (RHHBY) Xofluza for treating uncomplicated influenza and post-exposure prophylaxis of influenza in children aged one year and above.
Johnson & Johnson Is A Better Dividend Stock Than Roche, Despite A 20% Lower Yield
11:45am, Wednesday, 11'th Jan 2023
In the first part of this article, I provide easy-to-digest overviews of U.S. pharmaceutical and medical technology giant Johnson & Johnson and Swiss biologics and diagnostics king Roche Holding AG. I
Ranking The Top 10 Pharmaceuticals By Pipeline
11:44pm, Monday, 09'th Jan 2023
The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance.
Kronos Bio's stock rallies after announcing drug-discovery deal with Roche
08:23am, Monday, 09'th Jan 2023
Shares of Kronos Bio Inc. KRON, +2.38% jumped 25% in premarket trading on Monday after the company announced a development deal with Roche Holding's ROG, -0.46% Genentech. Kronos has a drug discovery
Roche's (RHHBY) Cancer Drug Glofitamab Gets FDA Priority Review
12:02pm, Friday, 06'th Jan 2023
The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.
International Wide-Moat Stocks On Sale - The January 2023 Heat Map
10:48pm, Thursday, 05'th Jan 2023
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.
We're not near a bull market, David Roche says
05:26am, Tuesday, 03'rd Jan 2023
David Roche, president at Independent Strategy, says "we narrowly escaped recession."
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
09:00am, Monday, 02'nd Jan 2023
Which of these companies is better able to replace declining COVID-19-related sales?
